Atherogenic Lipoprotein Subfractions Determined by Ion Mobility and First Cardiovascular Events After Random Allocation to High-Intensity Statin or Placebo: The Justification for the Use of @entity6817 in Prevention: An Intervention Trial Evaluating XXXX (JUPITER) Trial.

@entity1 @entity8671 @entity755 @entity65 @entity204 @entity6817 @entity165 @entity1851
BACKGROUND: @entity65 ( @entity65 ) can occur in individuals with low low-density lipoprotein (LDL) @entity165 (LDL-C). We investigated whether detailed measures of LDL subfractions and other lipoproteins can be used to assess @entity65 risk in a population with both low LDL-C and high @entity1851 who were randomized to high-intensity statin or placebo. METHODS AND RESULTS: In 11   186 Justification for the Use of @entity6817 in Prevention: An Intervention Trial Evaluating @entity8671 (JUPITER) @entity1 , we tested whether lipids, apolipoproteins, and ion mobility-measured particle concentrations at baseline and after random allocation to @entity8671 20 mg/d or placebo were associated with first @entity65 events (n=307) or @entity65 /all-cause @entity204 (n=522). In placebo-allocated @entity1 , baseline LDL-C was not associated with @entity65 (adjusted hazard ratio [HR] per SD, 1.03; 95% confidence interval [CI], 0.88-1.21). In contrast, associations with @entity65 events were observed for baseline non-high-density lipoprotein (HDL) @entity165 (HR, 1.18; 95% CI, 1.01-1.38), @entity755 (HR, 1.28; 95% CI, 1.11-1.48), and ion mobility-measured non-HDL particles (HR, 1.19; 95% CI, 1.05-1.35) and LDL particles (HR, 1.21; 95% CI, 1.07-1.37). Association with @entity65 events was also observed for several LDL and very-low-density lipoprotein subfractions but not for ion mobility-measured HDL subfractions. In statin-allocated @entity1 , @entity65 events were associated with on-treatment LDL-C, non-HDL @entity165 , and @entity755 ; these were also associated with @entity65 /all-cause @entity204 , as were several LDL and very-low-density lipoprotein subfractions, albeit with a pattern of association that differed from the baseline risk. CONCLUSIONS: In JUPITER, baseline LDL-C was not associated with @entity65 events, in contrast with significant associations for non-HDL @entity165 and atherogenic particles: @entity755 and ion mobility-measured non-HDL particles, LDL particles, and select subfractions of very-low-density lipoprotein particles and LDL particles. During high-intensity statin therapy, on-treatment levels of LDL-C and atherogenic particles were associated with residual risk of @entity65 /all-cause @entity204 . CLINICAL TRIAL REGISTRATION: URL: http://www.clinicaltrials.gov. Unique identifier: NCT00239681.
